Last reviewed 2026-04-19 · How we verify
Home › Drugs › Shanghai Juncell Therapeutics › Engineering Tumor Infiltrating Lymphocytes Engineering Tumor Infiltrating Lymphocytes
At a glance
Generic name Engineering Tumor Infiltrating Lymphocytes Also known as GC203 TIL Sponsor Shanghai Juncell Therapeutics Modality Biologic Phase Phase 1
Approved indications
No approved indications tracked.
Common side effects
No common side effects on file.
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
Drug Landscape https://druglandscape.com/drug/engineering-tumor-infiltrating-lymphocytes · Machine-readable: markdown · JSON · Editorial policy: /editorial-policy
Not medical advice. Information on this page is collated from primary regulatory and clinical-trial sources for research purposes. It is not a substitute for consultation with a licensed healthcare professional. See our editorial policy for sourcing and methodology.